Trade Report: Today, Amicus Therapeutics Inc. (FOLD) Given “Buy” Rating at Chardan Capital

Today, Amicus Therapeutics Inc. (FOLD) Given “Buy” Rating at Chardan Capital

Amicus Therapeutics Inc. (NASDAQ:FOLD)‘s stock had its “buy” rating restated by investment analysts at Chardan Capital in a research report issued to clients and investors on Tuesday.

Several other equities research analysts have also weighed in on the company. Zacks Investment Research lowered Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 11th. Cowen and Company reissued an “outperform” rating and issued a $15.00 price objective on shares of Amicus Therapeutics in a report on Tuesday, November 8th. Finally, Leerink Swann reissued a “buy” rating and issued a $17.00 price objective on shares of Amicus Therapeutics in a report on Tuesday, November 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $12.19.

Amicus Therapeutics (NASDAQ:FOLD) opened at 8.32 on Tuesday. Amicus Therapeutics has a 52 week low of $4.98 and a 52 week high of $11.02. The firm’s 50-day moving average price is $7.82 and its 200 day moving average price is $6.97. The firm’s market cap is $1.18 billion.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.01. The business had revenue of $2.10 million for the quarter, compared to analysts’ expectations of $1.71 million. Equities analysts forecast that Amicus Therapeutics will post ($1.38) earnings per share for the current fiscal year.

In related news, SVP Daphne Quimi sold 8,546 shares of the business’s stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $8.00, for a total value of $68,368.00. Following the completion of the sale, the senior vice president now owns 24,189 shares in the company, valued at approximately $193,512. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO William D. Baird III sold 20,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 20th. The stock was sold at an average price of $8.00, for a total value of $164,000.00. Following the completion of the sale, the chief financial officer now owns 56,450 shares of the company’s stock, valued at approximately $451,600. The disclosure for this sale can be found here. Insiders own 3.40% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in FOLD. Candriam Luxembourg S.C.A. increased its stake in Amicus Therapeutics by 14.5% in the second quarter. Candriam Luxembourg S.C.A. now owns 709,900 shares of the biopharmaceutical company’s stock worth $3,876,000 after buying an additional 90,000 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Amicus Therapeutics by 19.8% in the second quarter. Bank of New York Mellon Corp now owns 649,235 shares of the biopharmaceutical company’s stock worth $3,545,000 after buying an additional 107,215 shares during the period. State Board of Administration of Florida Retirement System boosted its position in shares of Amicus Therapeutics by 36.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 55,248 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 14,810 shares during the period. DekaBank Deutsche Girozentrale boosted its position in shares of Amicus Therapeutics by 31.5% in the second quarter. DekaBank Deutsche Girozentrale now owns 70,900 shares of the biopharmaceutical company’s stock worth $384,000 after buying an additional 17,000 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Amicus Therapeutics by 11.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 459,801 shares of the biopharmaceutical company’s stock worth $2,511,000 after buying an additional 48,690 shares during the period.

About Amicus Therapeutics

Related posts

Leave a Comment

Trade Report: Today, Amicus Therapeutics Inc. (FOLD) Given “Buy” Rating at Chardan Capital

Today, Amicus Therapeutics Inc. (FOLD) Given “Buy” Rating at Chardan Capital

Amicus Therapeutics Inc. (NASDAQ:FOLD)‘s stock had its “buy” rating restated by investment analysts at Chardan Capital in a research report issued to clients and investors on Tuesday.

Several other equities research analysts have also weighed in on the company. Zacks Investment Research lowered Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 11th. Cowen and Company reissued an “outperform” rating and issued a $15.00 price objective on shares of Amicus Therapeutics in a report on Tuesday, November 8th. Finally, Leerink Swann reissued a “buy” rating and issued a $17.00 price objective on shares of Amicus Therapeutics in a report on Tuesday, November 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $12.19.

Amicus Therapeutics (NASDAQ:FOLD) opened at 8.32 on Tuesday. Amicus Therapeutics has a 52 week low of $4.98 and a 52 week high of $11.02. The firm’s 50-day moving average price is $7.82 and its 200 day moving average price is $6.97. The firm’s market cap is $1.18 billion.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.01. The business had revenue of $2.10 million for the quarter, compared to analysts’ expectations of $1.71 million. Equities analysts forecast that Amicus Therapeutics will post ($1.38) earnings per share for the current fiscal year.

In related news, SVP Daphne Quimi sold 8,546 shares of the business’s stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $8.00, for a total value of $68,368.00. Following the completion of the sale, the senior vice president now owns 24,189 shares in the company, valued at approximately $193,512. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO William D. Baird III sold 20,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 20th. The stock was sold at an average price of $8.00, for a total value of $164,000.00. Following the completion of the sale, the chief financial officer now owns 56,450 shares of the company’s stock, valued at approximately $451,600. The disclosure for this sale can be found here. Insiders own 3.40% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in FOLD. Candriam Luxembourg S.C.A. increased its stake in Amicus Therapeutics by 14.5% in the second quarter. Candriam Luxembourg S.C.A. now owns 709,900 shares of the biopharmaceutical company’s stock worth $3,876,000 after buying an additional 90,000 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Amicus Therapeutics by 19.8% in the second quarter. Bank of New York Mellon Corp now owns 649,235 shares of the biopharmaceutical company’s stock worth $3,545,000 after buying an additional 107,215 shares during the period. State Board of Administration of Florida Retirement System boosted its position in shares of Amicus Therapeutics by 36.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 55,248 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 14,810 shares during the period. DekaBank Deutsche Girozentrale boosted its position in shares of Amicus Therapeutics by 31.5% in the second quarter. DekaBank Deutsche Girozentrale now owns 70,900 shares of the biopharmaceutical company’s stock worth $384,000 after buying an additional 17,000 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Amicus Therapeutics by 11.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 459,801 shares of the biopharmaceutical company’s stock worth $2,511,000 after buying an additional 48,690 shares during the period.

About Amicus Therapeutics

Related posts

Leave a Comment